Does the media refer more to TLRY or SPRB?

In the previous week, Tilray Brands had 16 more articles in the media than Spruce Biosciences. MarketBeat recorded 19 mentions for Tilray Brands and 3 mentions for Spruce Biosciences. Spruce Biosciences' average media sentiment score of 0.88 beat Tilray Brands' score of 0.83 indicating that Spruce Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tilray Brands 6 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Spruce Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is RZLT or SPRB more profitable?

Rezolute's return on equity of -58.82% beat Spruce Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Rezolute N/A -58.82% -54.48% Spruce Biosciences N/A -155.40% -101.67%

Does the media favor RZLT or SPRB?

In the previous week, Rezolute had 2 more articles in the media than Spruce Biosciences. MarketBeat recorded 5 mentions for Rezolute and 3 mentions for Spruce Biosciences. Rezolute's average media sentiment score of 1.41 beat Spruce Biosciences' score of 0.88 indicating that Rezolute is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rezolute 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spruce Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SPRB or PROK?

In the previous week, Spruce Biosciences and Spruce Biosciences both had 3 articles in the media. Spruce Biosciences' average media sentiment score of 0.88 beat ProKidney's score of 0.62 indicating that Spruce Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spruce Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ProKidney 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is VALN or SPRB more profitable?

Spruce Biosciences has a net margin of 0.00% compared to Valneva's net margin of -88.87%. Valneva's return on equity of -107.63% beat Spruce Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Valneva -88.87% -107.63% -33.02% Spruce Biosciences N/A -155.40% -101.67%

Does the media favor VALN or SPRB?

In the previous week, Spruce Biosciences had 1 more articles in the media than Valneva. MarketBeat recorded 3 mentions for Spruce Biosciences and 2 mentions for Valneva. Spruce Biosciences' average media sentiment score of 0.88 beat Valneva's score of 0.62 indicating that Spruce Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Valneva 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spruce Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SPRB or CABA more profitable?

Cabaletta Bio's return on equity of -131.58% beat Spruce Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Spruce Biosciences N/A -155.40% -101.67% Cabaletta Bio N/A -131.58% -96.46%

Spruce Biosciences (SPRB) Competitors

$41.60 -0.39 (-0.93%)

Closing price 07/28/2026 04:00 PM Eastern

Extended Trading

$41.78 +0.18 (+0.43%)

As of 04:05 AM Eastern

Compare

SPRB vs. TLRY, RZLT, PROK, VALN, and CABA

Should you buy Spruce Biosciences stock or one of its competitors? MarketBeat compares Spruce Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Spruce Biosciences include Tilray Brands (TLRY), Rezolute (RZLT), ProKidney (PROK), Valneva (VALN), and Cabaletta Bio (CABA). These companies are all part of the "pharmaceutical products" industry.

How does Spruce Biosciences compare to Tilray Brands?

Tilray Brands (NASDAQ:TLRY) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations.

Tilray Brands presently has a consensus price target of $11.00, indicating a potential upside of 172.95%. Spruce Biosciences has a consensus price target of $162.63, indicating a potential upside of 290.93%. Given Spruce Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Spruce Biosciences is more favorable than Tilray Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tilray Brands	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Spruce Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

In the previous week, Tilray Brands had 16 more articles in the media than Spruce Biosciences. MarketBeat recorded 19 mentions for Tilray Brands and 3 mentions for Spruce Biosciences. Spruce Biosciences' average media sentiment score of 0.88 beat Tilray Brands' score of 0.83 indicating that Spruce Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tilray Brands	6 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Spruce Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tilray Brands has a beta of 1.89, meaning that its stock price is 89% more volatile than the broader market. Comparatively, Spruce Biosciences has a beta of 3.16, meaning that its stock price is 216% more volatile than the broader market.

9.4% of Tilray Brands shares are held by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are held by institutional investors. 0.8% of Tilray Brands shares are held by company insiders. Comparatively, 4.3% of Spruce Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Spruce Biosciences has a net margin of 0.00% compared to Tilray Brands' net margin of -156.51%. Tilray Brands' return on equity of -3.31% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tilray Brands	-156.51%	-3.31%	-2.42%
Spruce Biosciences	N/A	-155.40%	-101.67%

Spruce Biosciences has lower revenue, but higher earnings than Tilray Brands. Spruce Biosciences is trading at a lower price-to-earnings ratio than Tilray Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tilray Brands	$821.31M	0.57	-$2.19B	-$13.65	N/A
Spruce Biosciences	$4.91M	23.30	-$38.97M	-$36.60	N/A

Summary

Spruce Biosciences beats Tilray Brands on 10 of the 16 factors compared between the two stocks.

How does Spruce Biosciences compare to Rezolute?

Rezolute (NASDAQ:RZLT) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations and valuation.

Rezolute's return on equity of -58.82% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rezolute	N/A	-58.82%	-54.48%
Spruce Biosciences	N/A	-155.40%	-101.67%

Rezolute has a beta of 0.54, indicating that its stock price is 46% less volatile than the broader market. Comparatively, Spruce Biosciences has a beta of 3.16, indicating that its stock price is 216% more volatile than the broader market.

Rezolute presently has a consensus target price of $9.38, indicating a potential upside of 90.55%. Spruce Biosciences has a consensus target price of $162.63, indicating a potential upside of 290.93%. Given Spruce Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Spruce Biosciences is more favorable than Rezolute.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rezolute	2 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50
Spruce Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

83.0% of Rezolute shares are owned by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are owned by institutional investors. 14.8% of Rezolute shares are owned by company insiders. Comparatively, 4.3% of Spruce Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Spruce Biosciences has higher revenue and earnings than Rezolute. Rezolute is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rezolute	N/A	N/A	-$74.41M	-$0.82	N/A
Spruce Biosciences	$4.91M	23.30	-$38.97M	-$36.60	N/A

In the previous week, Rezolute had 2 more articles in the media than Spruce Biosciences. MarketBeat recorded 5 mentions for Rezolute and 3 mentions for Spruce Biosciences. Rezolute's average media sentiment score of 1.41 beat Spruce Biosciences' score of 0.88 indicating that Rezolute is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rezolute	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Spruce Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Spruce Biosciences beats Rezolute on 7 of the 13 factors compared between the two stocks.

How does Spruce Biosciences compare to ProKidney?

Spruce Biosciences (NASDAQ:SPRB) and ProKidney (NASDAQ:PROK) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, media sentiment, profitability and earnings.

Spruce Biosciences has a beta of 3.16, suggesting that its share price is 216% more volatile than the broader market. Comparatively, ProKidney has a beta of 1.61, suggesting that its share price is 61% more volatile than the broader market.

91.7% of Spruce Biosciences shares are held by institutional investors. Comparatively, 51.6% of ProKidney shares are held by institutional investors. 4.3% of Spruce Biosciences shares are held by insiders. Comparatively, 39.8% of ProKidney shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Spruce Biosciences has higher revenue and earnings than ProKidney. ProKidney is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spruce Biosciences	$4.91M	23.30	-$38.97M	-$36.60	N/A
ProKidney	$890K	522.67	-$68.99M	-$0.53	N/A

Spruce Biosciences currently has a consensus price target of $162.63, indicating a potential upside of 290.93%. ProKidney has a consensus price target of $12.00, indicating a potential upside of 679.22%. Given ProKidney's higher probable upside, analysts plainly believe ProKidney is more favorable than Spruce Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spruce Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
ProKidney	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Spruce Biosciences and Spruce Biosciences both had 3 articles in the media. Spruce Biosciences' average media sentiment score of 0.88 beat ProKidney's score of 0.62 indicating that Spruce Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spruce Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ProKidney	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Spruce Biosciences has a net margin of 0.00% compared to ProKidney's net margin of -8,131.50%. ProKidney's return on equity of 0.00% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spruce Biosciences	N/A	-155.40%	-101.67%
ProKidney	-8,131.50%	N/A	-21.39%

Summary

Spruce Biosciences beats ProKidney on 9 of the 16 factors compared between the two stocks.

How does Spruce Biosciences compare to Valneva?

Valneva (NASDAQ:VALN) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.

In the previous week, Spruce Biosciences had 1 more articles in the media than Valneva. MarketBeat recorded 3 mentions for Spruce Biosciences and 2 mentions for Valneva. Spruce Biosciences' average media sentiment score of 0.88 beat Valneva's score of 0.62 indicating that Spruce Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Valneva	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Spruce Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Valneva presently has a consensus target price of $11.98, indicating a potential upside of 136.66%. Spruce Biosciences has a consensus target price of $162.63, indicating a potential upside of 290.93%. Given Spruce Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Spruce Biosciences is more favorable than Valneva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valneva	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Spruce Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Valneva has a beta of 1.77, suggesting that its stock price is 77% more volatile than the broader market. Comparatively, Spruce Biosciences has a beta of 3.16, suggesting that its stock price is 216% more volatile than the broader market.

Spruce Biosciences has a net margin of 0.00% compared to Valneva's net margin of -88.87%. Valneva's return on equity of -107.63% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valneva	-88.87%	-107.63%	-33.02%
Spruce Biosciences	N/A	-155.40%	-101.67%

11.4% of Valneva shares are held by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are held by institutional investors. 14.9% of Valneva shares are held by company insiders. Comparatively, 4.3% of Spruce Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Spruce Biosciences has lower revenue, but higher earnings than Valneva. Valneva is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valneva	$197.56M	2.43	-$130.33M	-$1.87	N/A
Spruce Biosciences	$4.91M	23.30	-$38.97M	-$36.60	N/A

Summary

Spruce Biosciences beats Valneva on 11 of the 16 factors compared between the two stocks.

How does Spruce Biosciences compare to Cabaletta Bio?

Spruce Biosciences (NASDAQ:SPRB) and Cabaletta Bio (NASDAQ:CABA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

Cabaletta Bio's return on equity of -131.58% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spruce Biosciences	N/A	-155.40%	-101.67%
Cabaletta Bio	N/A	-131.58%	-96.46%

91.7% of Spruce Biosciences shares are held by institutional investors. 4.3% of Spruce Biosciences shares are held by company insiders. Comparatively, 6.4% of Cabaletta Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Spruce Biosciences has a beta of 3.16, indicating that its stock price is 216% more volatile than the broader market. Comparatively, Cabaletta Bio has a beta of 3.26, indicating that its stock price is 226% more volatile than the broader market.

Spruce Biosciences currently has a consensus target price of $162.63, indicating a potential upside of 290.93%. Cabaletta Bio has a consensus target price of $15.50, indicating a potential upside of 467.77%. Given Cabaletta Bio's higher possible upside, analysts plainly believe Cabaletta Bio is more favorable than Spruce Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spruce Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Spruce Biosciences has higher revenue and earnings than Cabaletta Bio. Cabaletta Bio is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spruce Biosciences	$4.91M	23.30	-$38.97M	-$36.60	N/A
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.96	N/A

In the previous week, Spruce Biosciences had 2 more articles in the media than Cabaletta Bio. MarketBeat recorded 3 mentions for Spruce Biosciences and 1 mentions for Cabaletta Bio. Cabaletta Bio's average media sentiment score of 0.97 beat Spruce Biosciences' score of 0.88 indicating that Cabaletta Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Spruce Biosciences	Positive
Cabaletta Bio	Positive

Summary

Spruce Biosciences and Cabaletta Bio tied by winning 7 of the 14 factors compared between the two stocks.

Get Spruce Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SPRB vs. The Competition

Export

Metric	Spruce Biosciences	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$115.57M	$946.09M	$7.08B	$12.19B
Dividend Yield	N/A	4.84%	2.66%	8.55%
P/E Ratio	-1.14	1.52	27.27	23.75
Price / Sales	23.30	109.14	578.56	109.45
Price / Cash	N/A	20.06	49.60	59.05
Price / Book	1.05	8.45	10.11	6.06
Net Income	-$38.97M	-$3.57M	$3.60B	$336.44M
7 Day Performance	-6.73%	0.55%	-0.95%	-1.50%
1 Month Performance	-25.55%	-7.88%	-3.59%	-4.62%
1 Year Performance	366.89%	27.13%	20.53%	15.02%

Spruce Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SPRB Spruce Biosciences	2.4961 of 5 stars	$41.60 -0.9%	$162.63 +290.9%	+404.2%	$115.57M	$4.91M	N/A	20
TLRY Tilray Brands	2.9711 of 5 stars	$4.24 +0.2%	$11.00 +159.4%	-42.4%	$494.17M	$821.31M	N/A	2,842	Trending News Earnings Report
RZLT Rezolute	3.5956 of 5 stars	$5.09 +14.4%	$9.38 +84.2%	-22.9%	$490.12M	N/A	N/A	40
PROK ProKidney	1.9283 of 5 stars	$1.60 +2.2%	$12.00 +652.4%	-50.0%	$481.79M	$890K	N/A	3
VALN Valneva	2.5752 of 5 stars	$4.93 +1.9%	$11.98 +142.9%	-33.5%	$467.81M	$197.56M	N/A	700

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SPRB) was last updated on 7/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Spruce Biosciences (SPRB) Competitors

SPRB vs. TLRY, RZLT, PROK, VALN, and CABA

How does Spruce Biosciences compare to Tilray Brands?

Summary

How does Spruce Biosciences compare to Rezolute?

Summary

How does Spruce Biosciences compare to ProKidney?

Summary

How does Spruce Biosciences compare to Valneva?

Summary

How does Spruce Biosciences compare to Cabaletta Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRB vs. The Competition

Spruce Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Spruce Biosciences (SPRB) Competitors

SPRB vs. TLRY, RZLT, PROK, VALN, and CABA

How does Spruce Biosciences compare to Tilray Brands?

Do analysts prefer TLRY or SPRB?

Does the media refer more to TLRY or SPRB?

Which has more volatility and risk, TLRY or SPRB?

Do institutionals and insiders believe in TLRY or SPRB?

Is TLRY or SPRB more profitable?

Which has higher earnings and valuation, TLRY or SPRB?

Summary

How does Spruce Biosciences compare to Rezolute?

Is RZLT or SPRB more profitable?

Which has more volatility & risk, RZLT or SPRB?

Do analysts prefer RZLT or SPRB?

Do institutionals & insiders believe in RZLT or SPRB?

Which has better earnings and valuation, RZLT or SPRB?

Does the media favor RZLT or SPRB?

Summary

How does Spruce Biosciences compare to ProKidney?

Which has more risk & volatility, SPRB or PROK?

Do institutionals and insiders hold more shares of SPRB or PROK?

Which has higher valuation & earnings, SPRB or PROK?

Do analysts recommend SPRB or PROK?

Does the media favor SPRB or PROK?

Is SPRB or PROK more profitable?

Summary

How does Spruce Biosciences compare to Valneva?

Does the media favor VALN or SPRB?

Do analysts recommend VALN or SPRB?

Which has more risk and volatility, VALN or SPRB?

Is VALN or SPRB more profitable?

Do institutionals & insiders believe in VALN or SPRB?

Which has preferable earnings and valuation, VALN or SPRB?

Summary

How does Spruce Biosciences compare to Cabaletta Bio?

Is SPRB or CABA more profitable?

Do institutionals and insiders believe in SPRB or CABA?

Which has more risk & volatility, SPRB or CABA?

Do analysts recommend SPRB or CABA?

Which has preferable valuation & earnings, SPRB or CABA?

Does the media prefer SPRB or CABA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRB vs. The Competition

Spruce Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools